Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Amy Vega Takes A Novel Approach To Nursing Education
When you think of continuing education for nursing, you may imagine medical textbooks, complicated graphs and loads of acronyms. Well, Amy Glenn Vega hopes to transform continuing education by taking nursing lessons and crafting them into steamy page-turners nurses can read while cozying up next to the fireplace in their favorite comfy chairs.

Medtronic Receives FDA Approval For BRYAN(R) Cervical Disc System
Medtronic, Inc. (NYSE: MDT) announced that it received U.S. Food and Drug Administration (FDA) approval to market the BRYAN® Cervical Disc System for the treatment of single-level cervical disc disease (radiculopathy and/or myelopathy). In July 2007, Medtronic"s PRESTIGE® Cervical Disc was the first artificial cervical disc to be approved by the FDA. With the BRYAN® Disc and the PRESTIGE® Disc, Medtronic now offers a diverse portfolio of artificial cervical discs that address varying philosophies among spine surgeons about optimal implant materials, fixation methods, surgical techniques, and other unique design features.
News of the day
Cigarette Smoking Does Not Affect Everyone In Same Way
Cigarette smoking induced COPD, or chronic obstructive pulmonary disease, is a disease that results in severe breathing difficulty. According to World Health Organization (WHO) it is the fourth leading killer worldwide. However the mechanisms responsible for some smokers developing COPD and others evading the disease have not been well understood.
Endocrinology

Thalidomide Does Not Improve Survival In Small Cell Lung Cancer: Journal Of The National Cancer Institute News Brief

Treating patients with thalidomide in combination with chemotherapy for small cell lung cancer (SCLC) did not improve their survival but did increase their risk of blood clots, according to a new study published online July 16 in the Journal of the National Cancer Institute. Siow Ming Lee, M.D., of the Department of Oncology, University Hospital in London, and colleagues randomly assigned 724 SCLC patients to take either a placebo or thalidomide. Used in treating some other cancers, thalidomide is an anti-angiogenic drug, i.e., it targets and suppresses the formation of new blood vessels that tumors need to survive and grow. In this randomized double-blind trial, patients received 100-200 milligrams daily for up to two years. The researchers found no evidence of a survival difference between the two groups. The median overall survival for patients who received the placebo was 10.5 months. For patients who took thalidomide capsules, it was 10.1 months. Patients treated with thalidomide, however, had higher risk of thrombotic events. "Together, these results suggest that targeting anti-angiogenesis in SCLC may not work as well as in multiple myeloma or colorectal cancer, perhaps because of differences in the angiogenic pathways involved in SCLC," the authors write. In an accompanying editorial, Curzio RÃøegg, M.D., of the Division of Experimental Oncology at the University of Lausanne in Switzerland, and Solange Peters, M.D., Ph.D., of the Clinical Oncology Service at the University of Lausanne, note that this study"s results, as well as similar, negative results from previous studies, should lead to a fresh look at the basic biology of SCLC and of the putative anti-angiogenic activity of thalidomide. "Rather than running from failure to failure, it may be more reasonable to go back to experimental work, including the development and analysis of transgenic SCLC models, to better understand SCLC biology and identify robust therapeutic targets," the editorialists write. Steve Graff Journal of the National Cancer Institute


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009